BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 15, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2007

View Archived Issues

Recent Bayer patents report novel therapeutic agents for urological disorders

Read More

New agents for treating neurological disorders disclosed in recent patent literature

Read More

New therapeutic strategies for cancer imparted in recent patents

Read More

BENCHMRK studies reveal activity of raltegravir in triple-class resistant HIV

Read More

Interleukin-12 gene therapy safe in phase I ovarian cancer study

Read More

Maraviroc effective in phase IIb/III studies in CCR5-tropic HIV-1

Read More

rAAV HIV vaccine safe, well tolerated in healthy subjects

Read More

Entecavir selects for HIV resistance mutations

Read More

Idenix develops potent and selective anti-HIV agents

Read More

Treatment complete in phase II osteoarthritis study of Indaflex

Read More

MIV-701 begins clinical studies for osteoporosis

Read More

Novartis Consumer Health to copromote Vusion ointment to U.S. pediatricians

Read More

Encouraging proof-of-concept results for PA-325

Read More

Enrollment complete in phase I/II study of ALKS-29 in alcohol dependence

Read More

Financing at TransOral to support Intermezzo NDA filing

Read More

Enrollment completed in phase II study of CTA-018 for psoriasis

Read More

Sinovac updates progress of pandemic influenza vaccine study

Read More

Sunesis studies SNS-032 for advanced B-cell malignancies in clinic

Read More

Phase II study of faropenem in acute otitis media meets primary objective

Read More

Panzem NCD studied with Sutent in metastatic renal cell carcinoma

Read More

Roche's HPV tests accepted for FDA review

Read More

Enrollment completed in phase IIb study of AeroLEF

Read More

Sankyo and Biota license Hovione's inhaler technology for influenza

Read More

Amarin acquires rights to nasal lorazepam for emergency epilepsy seizures

Read More

Target enrollment reached in phase III trials of Puricase

Read More

Flurizan shows benefit in mild Alzheimer's patients

Read More

Topline MERLIN TIMI-36 results for ranolazine

Read More

Moli-1901 improves lung function in cystic fibrosis study

Read More

Lipitor approved for five new indications in heart disease

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 12, 2026.
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • Illustration of Lactobacillus

    Microbiota modulates the antidepressant effects of GLP-1 analogues

    BioWorld Science
    Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • Microscopic image of chronic myeloid leukemia

    Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

    BioWorld
    Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing